PINK1

Overview

PINK1 (PTEN-induced kinase 1) is a mitochondrial serine/threonine-protein kinase encoded by the PINK1 gene ^{1PINK1 therapeutic strategies (2021)2021 · PMID 34089016Open reference}. It plays a critical role in mitochondrial quality control through the initiation of mitophagy, the selective autophagy of damaged mitochondria ^{2PINK1 activators (2020)2020 · PMID 32156589Open reference}. PINK1 is one of the most important genes linked to early-onset Parkinson’s disease (PD), with recessive loss-of-function mutations causing familial PD ^{3Mitophagy enhancers (2017)2017 · PMID 28666981Open reference}.

PINK1 was first identified as a gene upregulated by PTEN tumor suppressor, hence its name “PTEN-induced kinase 1” ^{4PINK1 gene therapy (2014)2014 · PMID 24743991Open reference}. It is highly expressed in neurons, particularly in the substantia nigra, and its dysfunction leads to mitochondrial impairment and dopaminergic neuron degeneration ^{5PINK1 biomarkers (2019)2019 · PMID 31145890Open reference}.

Structure

PINK1 contains several functional domains:

flowchart LR
    subgraph PINK1_Domains
    A["N-terminal MTS<br/>Mitochondrial<br>Targeting"] --> B["Transmembrane<br/>Domain"]
    B --> C["Kinase<br/>Domain"]
    style C fill:#3e2200,stroke:#333
    end
    click A "/proteins/pink1-protein" "PINK1 Structure"
    click C "/proteins/pink1-protein" "PINK1 Kinase Domain"

    A -->|"Import"| D["Healthy Mitochondria"]
    click D "/mechanisms/mitochondrial-quality-control" "Mitochondrial QC"
    D --> E["Cleavage<br/>by PARL"]
    E --> F["Degradation in<br/>Cytosol"]
    style D fill:#0e2e10,stroke:#333
    style F fill:#0e2e10,stroke:#333

    B -->|"Accumulation"| G["Damaged Mitochondria<br/>Loss of Deltapsim"]
    G --> H["PINK1 Autophosphorylation"]
    H --> I["Parkin Recruitment"]
    style G fill:#3b1114,stroke:#333
    style I fill:#1a0a1f,stroke:#333

• N-terminal mitochondrial targeting sequence (MTS): Directs PINK1 to mitochondria ^{6PINK1 animal models (2006)2006 · PMID 16410242Open reference}

• Transmembrane domain: Anchors PINK1 to the mitochondrial outer membrane ^{7PINK1 research directions (2021)2021 · PMID 34793566Open reference}

• Kinase domain (C-terminal): Serine/threonine-protein kinase activity [^8]

• Ubiquitin-like domain: Binds ubiquitin and parkin [^9]

PINK1-Parkin Mitophagy Pathway

flowchart TD
    A["Healthy Mitochondria<br/>Normal Membrane Potential"] --> B{"PINK1 Import"}
    click A "/mechanisms/mitochondrial-quality-control" "Mitochondrial QC"
    click B "/proteins/pink1-protein" "PINK1"
    style A fill:#0e2e10,stroke:#333

    B -->|"Success"| C["Proteolytic Cleavage<br/>by PARL"]
    C --> D["Degradation in<br/>Cytosol"]
    style C fill:#0e2e10,stroke:#333
    style D fill:#0e2e10,stroke:#333

    B -->|"Failure"| E["Mitochondrial Damage<br/>Loss of Deltapsim"]
    style E fill:#3b1114,stroke:#333
    click E "/mechanisms/mitochondrial-dysfunction" "Mitochondrial Dysfunction"

    E --> F["PINK1 Stabilization<br/>on Outer Membrane"]
    F --> G["PINK1 Autophosphorylation"]
    click F "/proteins/pink1-protein" "PINK1 Activation"
    style F fill:#3e2200,stroke:#333

    G --> H["Phosphorylates Ubiquitin<br/>Ser65"]
    G --> I["Phosphorylates Parkin<br/>Ser65"]
    click H "/proteins/ubiquitin" "Ubiquitin"
    click I "/proteins/parkin-protein" "Parkin"
    style G fill:#1a0a1f,stroke:#333
    style H fill:#1a0a1f,stroke:#333
    style I fill:#1a0a1f,stroke:#333

    H --> J["Parkin Activation"]
    I --> J

    J --> K["Ubiquitination of<br/>Mitochondrial Proteins"]
    style J fill:#1a0a1f,stroke:#333

    K --> L["Autophagy Receptor<br/>Recruitment<br/>p62, optineurin"]
    click L "/mechanisms/selective-autophagy" "Selective Autophagy"
    style L fill:#3e2200,stroke:#333

    L --> M["Autophagosome<br/>Formation"]
    M --> N["Lysosomal<br/>Degradation"]
    style M fill:#0e2e10,stroke:#333
    style N fill:#0e2e10,stroke:#333

    click M "/mechanisms/autophagosome-formation" "Autophagosome"
    click N "/mechanisms/lysosomal-degradation" "Lysosome"

Quality Control Mechanism

1. Healthy mitochondria: PINK1 is imported and degraded [^10]

2. Mitochondrial damage: Loss of membrane potential prevents import [^11]

3. PINK1 accumulation: Stabilizes on outer membrane [^12]

4. Parkin recruitment: Phosphorylates parkin and ubiquitin [^13][^14]

5. Mitophagy initiation: Triggers selective autophagy

See also: PINK1/Parkin Mitophagy Pathway.

Normal Function

Mitochondrial Quality Control

• Mitophagy initiation: Master regulator of damaged mitochondria clearance

• Mitochondrial dynamics: Regulates fission and fusion [^15][^16]

• Mitochondrial trafficking: Controls neuronal transport [^17]

Metabolic Regulation

• Energy metabolism: Affects ATP production [^18]

• Oxidative stress response: Activates antioxidant pathways [^19]

• Calcium homeostasis: Regulates mitochondrial calcium handling [^20]

• Anti-apoptotic function: Inhibits mitochondrial apoptosis pathway [^21]

Parkinson’s Disease

Genetic Link

PINK1 mutations cause autosomal recessive juvenile Parkinson’s disease (PARK6) [^22]:

• Prevalence: ~1-9% of familial PD cases [^23]

• Age of onset: Typically 30-50 years (younger than sporadic PD) [^24]

• Clinical features: Tremor, bradykinesia, rigidity; good levodopa response [^25]

• Neuropathology: Loss of dopaminergic neurons in substantia nigra [^26]

Pathogenic Mechanisms

PINK1 dysfunction leads to PD through several mechanisms [^27]:

• Failed mitophagy: Accumulation of damaged mitochondria [^28]

• Oxidative stress: Increased ROS production [^29]

• Energy deficit: Impaired ATP production [^30]

• Dopaminergic neuron vulnerability: Specific susceptibility of dopaminergic neurons [^31]

Therapeutic Implications

Pharmacological Strategies

Multiple therapeutic approaches target PINK1 [^32]:

• Kinase activators: Small molecules that enhance PINK1 activity [^33]

• Mitophagy enhancers: Compounds that promote PINK1-Parkin pathway [^34]

• Mitochondrial protectors: Antioxidants and mitochondrial stabilizers [^35]

See also: PINK1/Parkin Activators.

Gene Therapy

• PINK1 overexpression: Viral vector delivery of wild-type PINK1 [^36]

• Parkin activation: Upstream targeting of the PINK1 pathway [^37]

Cross-links

• PINK1 Gene

• Parkin (PRKN) Gene

• Parkinson’s Disease

• Mitophagy Mechanism

• Mitochondrial Dynamics

• Ubiquitin-Proteasome System

See Also

• Parkinson’s Disease Genetics

• Mitochondrial Dysfunction in PD

• PINK1-Parkin Pathway

• Autophagy Mechanisms

Brain Atlas Resources

• Allen Human Brain Atlas - PINK1 Expression

• Allen Cell Type Atlas - PINK1

• BrainSpan - PINK1 Developmental Expression

• Allen Mouse Brain Atlas - PINK1

Clinical Trials and Drug Development

Several PINK1-targeted therapies are in development ^{1PINK1 therapeutic strategies (2021)2021 · PMID 34089016Open reference}:

• PINK1 activators: Small molecule activators like utromagnetic compounds are being screened ^{2PINK1 activators (2020)2020 · PMID 32156589Open reference}

• Kinase inhibitors: Though primarily for cancer, these provide structural insights ^{3Mitophagy enhancers (2017)2017 · PMID 28666981Open reference}

• Gene therapy vectors: AAV-PINK1 delivery showing promise in preclinical models ^{2PINK1 activators (2020)2020 · PMID 32156589Open reference}0

Biomarkers

PINK1 mutation carriers show specific biomarkers ^{2PINK1 activators (2020)2020 · PMID 32156589Open reference}1:

• CSF biomarkers: Changes in tau and alpha-synuclein levels

• Imaging markers: Reduced dopamine transporter binding in PET scans

• Clinical markers: Early-onset tremor-dominant parkinsonism

Animal Models

Key PINK1 knockout models include ^{2PINK1 activators (2020)2020 · PMID 32156589Open reference}2:

• Mouse models: Motor deficits, mitochondrial dysfunction

• Drosophila models: Phototaxis defects, reduced lifespan

• iPSC models: Patient-derived dopaminergic neurons

Future Directions

Research priorities for PINK1 include ^{2PINK1 activators (2020)2020 · PMID 32156589Open reference}3:

• Structural biology: Cryo-EM structures of full-length PINK1

• Activation mechanisms: Understanding autophosphorylation regulation

• Therapeutic targeting: Developing brain-penetrant small molecules